[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tyra Biosciences Inc (TYRA)

Tyra Biosciences Inc (TYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,041,525
  • Shares Outstanding, K 59,485
  • Annual Sales, $ 0 K
  • Annual Income, $ -119,950 K
  • EBIT $ -133 M
  • EBITDA $ -132 M
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.78

Options Overview Details

View History
  • Implied Volatility 107.56% (+1.11%)
  • Historical Volatility 55.21%
  • IV Percentile 39%
  • IV Rank 19.05%
  • IV High 357.21% on 09/12/25
  • IV Low 48.81% on 09/09/25
  • Expected Move (DTE 5) 5.02 (14.61%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 8
  • Volume Avg (30-Day) 31
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 1,749
  • Open Int (30-Day) 2,588
  • Expected Range 29.31 to 39.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.60
  • Number of Estimates 7
  • High Estimate $-0.58
  • Low Estimate $-0.64
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) -27.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.26 +6.39%
on 05/07/26
38.63 -11.16%
on 04/27/26
-2.81 (-7.57%)
since 04/08/26
3-Month
24.88 +37.94%
on 02/12/26
40.65 -15.57%
on 04/01/26
+3.32 (+10.71%)
since 02/06/26
52-Week
8.75 +292.23%
on 05/28/25
40.65 -15.57%
on 04/01/26
+24.25 (+240.81%)
since 05/08/25

Most Recent Stories

More News
Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif. , May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 34.32 (+4.32%)
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

- Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth-

TYRA : 34.32 (+4.32%)
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

- Launched " dabogratinib 3x3 "  strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -

TYRA : 34.32 (+4.32%)
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

CARLSBAD, Calif. , Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 34.32 (+4.32%)
Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif. , Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 34.32 (+4.32%)
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 34.32 (+4.32%)
Tyra Biosciences Announces Participation at Upcoming Investor Events

CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 34.32 (+4.32%)
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights

- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -

TYRA : 34.32 (+4.32%)
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-

TYRA : 34.32 (+4.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 36.58
2nd Resistance Point 35.57
1st Resistance Point 34.95
Last Price 34.32
1st Support Level 33.32
2nd Support Level 32.31
3rd Support Level 31.69

See More

52-Week High 40.65
Last Price 34.32
Fibonacci 61.8% 28.46
Fibonacci 50% 24.70
Fibonacci 38.2% 20.94
52-Week Low 8.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.